Size | Price | Stock | Qty |
---|---|---|---|
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Zolmitriptan (311C90; 311 C90; trade names AscoTop, Zomig, Zomigon, Zomigoro), an approved drug for the treatment of acute migraines, is a potent and highly selective 5-HT(1B/1D) receptor agonist of the triptan class.
Targets |
5-HT1B Receptor ( IC50 = 5.01 nM ); 5-HT1D Receptor ( IC50 = 0.63 nM ); 5-HT1F Receptor ( IC50 = 63.09 nM ); Human Endogenous Metabolite
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Animal Protocol |
Anaesthetized guinea-pigs
0, 3, 10, 30 μg/kg I.v. |
|
References |
Molecular Formula |
C16H21N3O2
|
|
---|---|---|
Molecular Weight |
287.36
|
|
Exact Mass |
287.17
|
|
Elemental Analysis |
C, 66.88; H, 7.37; N, 14.62; O, 11.14
|
|
CAS # |
139264-17-8
|
|
Related CAS # |
|
|
Appearance |
Solid powder
|
|
SMILES |
CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@H]3COC(=O)N3
|
|
InChi Key |
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
|
|
InChi Code |
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
|
|
Chemical Name |
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
|
|
Synonyms |
311C 90; Flezol; zolmitriptan; 311C90; 311 C90; trade names Zomig; Zomigon; AscoTop; Zomigoro
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: 2.5 mg/mL (8.70 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.4800 mL | 17.3998 mL | 34.7996 mL | |
5 mM | 0.6960 mL | 3.4800 mL | 6.9599 mL | |
10 mM | 0.3480 mL | 1.7400 mL | 3.4800 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05019430 | Recruiting | Drug: Zolmitriptan Drug: Cocaine |
Cocaine Use Disorder | William Stoops | October 15, 2021 | Early Phase 1 |
NCT03145467 | Completed | Drug: Paracetamol Drug: Zolmitriptan |
Acute Migraine Headache | Pamukkale University | January 2016 | Phase 4 |
NCT02745392 | Completed | Drug: ZP-Zolmitriptan Drug: Placebo |
Acute Migraine | Zosano Pharma Corporation | June 2016 | Phase 2 Phase 3 |
NCT00637286 | Completed | Drug: Zolmitriptan | Migraine | AstraZeneca | July 2004 | Phase 4 |
NCT00617747 | Completed | Drug: Zolmitriptan Drug: Placebo |
Migraine | AstraZeneca | September 2002 | Phase 3 |